Diagnosis of HIV/AIDS

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

Retrieved on: 
Thursday, April 4, 2024
CGM, Consultant, Negotiation, Conference, Growth, Data analysis, HIV, Himawari (satellites), Diabetes, World Health Organization, Acquisition, American depositary receipt, Diagnosis of HIV/AIDS, Units of paper quantity, Clinical trial, Injection, Balance sheet, Waveform, Pharmaceutical industry

DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.

Key Points: 
  • DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
  • We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings.
  • The assets and liabilities attributable to Fitzgerald Industries have been removed from our Consolidated Balance Sheet as of December 31, 2023.
  • Total revenues for Q4, 2023 were $13.4m which compares to $15.7m in Q4, 2022, a decrease of 14.6% and which were broken down as follows:

Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya

Retrieved on: 
Wednesday, December 27, 2023
USAID, Food, Diagnosis of HIV/AIDS, Research, WHO, Trinity, HIV, Pharmaceutical industry

DUBLIN, Ireland, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces it has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV.

Key Points: 
  • DUBLIN, Ireland, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces it has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV.
  • The Kenyan HIV screening programme is one of the largest in Africa, with an estimated 10 million HIV screening tests performed annually.
  • The implementation of the new HIV testing algorithm, that includes TrinScreen HIV, is expected to start in January 2024.
  • This adoption by Kenya is an endorsement of our new product, TrinScreen HIV, and provides Trinity Biotech with a significant opportunity to penetrate deeper into the HIV screening market across all of Africa.

Trinity Biotech Announces Q2 2023 Financial Results

Retrieved on: 
Tuesday, October 3, 2023
KPI, Clinical chemistry, Federal Food, Drug, and Cosmetic Act, Partnership, Q3, SG, HIV, Diagnosis of HIV/AIDS, Reference, Balance sheet, Ion exchange, U.S. FDA, Mayo Clinic Center for Innovation, Ministry, A1C, EBITDA, Traction, Autoimmune disease, Supply chain, Investment, World Health Organization, Ministry of Health (Kuwait), Units of paper quantity, Growth, FDA, Calibration, Glycated hemoglobin, Pharmaceutical industry, Beauty salon, Fine chemical, Retail, Medical device, Video game, Vaccine, Renewable energy, Creative industries, Bank, Quest, Q2, Finance, Health, Sjögren syndrome, Diabetes

DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023.

Key Points: 
  • DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023.
  • Total revenue for fiscal Q2, 2023 was $13.9m (excluding Fitzgerald Industries, which was disposed of in April 2023).
  • In August, Trinity Biotech received U.S. FDA 510(k) clearance for the Premier Resolution System, the automated analyzer for accurate & precise quantification of haemoglobin variants.
  • Total revenues for Q2, 2023 were $13.9m which compares to $15.4m in Q2, 2022, a decrease of 9.8% and which were broken down as follows:

South African men are much more likely to die from TB than women -- here's why

Retrieved on: 
Thursday, September 28, 2023
Man, University, Diabetes, HIV, Diagnosis of HIV/AIDS, Mobile Clinic (sports), TB, Epidemiology, Infection, Woman, Center, Research, Thembisa, Sale, Death, Incidence, Health, Patient, Tuberculosis, Mortality, Vice-Chancellor of the University of Cape Town, Smoking, Disease, Pharmaceutical industry, Birth control, Toy, Vaccine, Liquor

Our main finding was that men are 70% more likely to develop TB and die from the disease, compared to women.

Key Points: 
  • Our main finding was that men are 70% more likely to develop TB and die from the disease, compared to women.
  • We estimated that in 2019, 801 per 100,000 adult men developed TB while among women the rate was 478 per 100,000.
  • Current TB interventions focus on biomedical approaches emphasising preventive TB medication, diagnosing TB patients and treating them with anti-TB drugs.
  • The model showed that between 1990 and 2019, South African men developed TB and died at consistently higher rates than women.

THE ELTON JOHN AIDS FOUNDATION AWARDS GRANT TO SAN ANTONIO AIDS FOUNDATION AND CORAZÓN SAN ANTONIO TO END NEW HIV INFECTIONS IN BEXAR COUNTY

Retrieved on: 
Wednesday, September 27, 2023
Elton, Partnership, Young adult, HIV, STI, SSP, Homelessness, Diagnosis of HIV/AIDS, SAAF, Infection, Woman, CDC, Drop-in center, Organization, Elton John AIDS Foundation, AIDS, MSW, Diagnosis, MPH, SA, Mental health, Syringe, Pharmaceutical industry, Doctor of Philosophy, United

SAN ANTONIO, Sept. 27, 2023 /PRNewswire/ -- San Antonio AIDS Foundation (SAAF) and Corazón San Antonio are excited to announce their newest community impact collaboration "SAAF Spaces with Corazón," in partnership with the Elton John AIDS Foundation. This two-year, $500,000 grant will help SAAF and Corazón San Antonio expand their services in HIV outreach, testing, prevention, and syringe exchange while providing resources to sex workers and people experiencing homelessness.

Key Points: 
  • $500,000 Award from the Elton John AIDS Foundation Will Help Expand HIV and STI outreach, testing, prevention and linkage to care throughout San Antonio
    SAN ANTONIO, Sept. 27, 2023 /PRNewswire/ -- San Antonio AIDS Foundation (SAAF) and Corazón San Antonio are excited to announce their newest community impact collaboration "SAAF Spaces with Corazón," in partnership with the Elton John AIDS Foundation .
  • "In partnering with the Elton John AIDS Foundation, the San Antonio AIDS Foundation and Corazón San Antonio will be able to connect with otherwise marginalized communities to provide not just HIV prevention and access to care but to offer support services for people who use drugs," said Cherise Rohr-Allegrini, PhD, MPH, CEO of the San Antonio AIDS Foundation.
  • "The Elton John AIDS Foundation, San Antonio AIDS Foundation and Corazón San Antonio have a shared goal of revolutionalizing the model of HIV care by meeting communities where they are, outside of traditional healthcare settings," said Noelle Esquire, US Portfolio Lead at the Elton John AIDS Foundation.
  • For more information about the Elton John AIDS Foundation grant and services provided by the San Antonio AIDS Foundation and Corazón, visit SanAntonioAIDS.org , CorazonSA.org , or ejaf.org .

Trinity Biotech Announces Q1 2023 Financial Results

Retrieved on: 
Thursday, July 6, 2023
Clinical chemistry, Total, Total addressable market, AACC, Diabetes, HIV, Diagnosis of HIV/AIDS, Tams, Sale, American Association for Clinical Chemistry, Capital, World Health Organization, Units of paper quantity, Growth, FDA, Calibration, Glycated hemoglobin, Pharmaceutical industry, Retail, Video game, Cryptocurrency, Bank

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023.

Key Points: 
  • DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023.
  • Partly offsetting these revenue gains are lower revenues from low margin diabetes instrument deliveries, compared to Q1 2022.
  • Diabetes instrument placements were up approximately 17% in Q1, 2023 vs Q4, 2022.
  • Total revenues for Q1, 2023 were $14.8m which compares to $15.7m in Q1, 2022, a decrease of 5.4% and which were broken down as follows:

HIV Rapid Test Kits Market Report 2023-2028: Increasing HIV Self-Testing Associated Government Policies Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 14, 2023
Infectious Diseases, Health, Medical Devices, Organization, OraQuick, HIV, Viral, Government, Blood, OraSure Technologies, United Nations, HIV/AIDS, Developed country, Saliva, Patient, Eastern, Lancet, WHO, Power-on self-test, Death, Immune system, Knowledge, Plasma, Joint, Antibody, Disease, DBS, Serum, Joint United Nations Programme on HIV/AIDS, Infection, AIDS, Prevalence, Diagnosis of HIV/AIDS, COVID-19, UNAIDS, Pharmaceutical industry, Vaccine, Central Europe

The global HIV rapid test kits market size is expected to grow at a CAGR of 2.70% during 2022 to 2028.

Key Points: 
  • The global HIV rapid test kits market size is expected to grow at a CAGR of 2.70% during 2022 to 2028.
  • These steps lead to an increase in demand for HIVST that directly impact the HIV rapid test kits market.
  • The application of digital tools in HIV management is increasing that expected to fuel the HIV rapid test kits market.
  • The increasing access to HIV rapid test kits through health authorities and vendor activities and the acceptance of self-testing kits for HIV management are increasing simultaneously, fueling the HIV rapid test kits market growth.

GoodRx Offers Free Telehealth Appointments to Florida Residents Affected by Hurricane Ian

Retrieved on: 
Tuesday, October 4, 2022
Health, Apps, Applications, Technology, Telemedicine, Virtual Medicine, Health Technology, General Health, Pharmaceutical, Physician, SEC, Technology, Private Securities Litigation Reform Act, Health, Â, Diagnosis of HIV/AIDS, Insurance, HIV, Lists of disasters, Digital, Acquisition, Tropical cyclone, Urinary tract infection, Health insurance, GoodRx

GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it is offering free online healthcare provider visits to Florida residents impacted by Hurricane Ian.

Key Points: 
  • GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it is offering free online healthcare provider visits to Florida residents impacted by Hurricane Ian.
  • GoodRx Care can also be used to get quick access to medication that may have been damaged in the storm or left behind during evacuation.
  • Residents in need can also find quality health information from physicians on relevant topics or questions at GoodRx Health .
  • In the wake of Hurricane Ians destruction, we want to ensure that Florida residents are able to take care of themselves and prioritize their health, said Doug Hirsch, co-founder and co-CEO of GoodRx.

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

Retrieved on: 
Tuesday, September 20, 2022
Emory, Health, Government, Algorithm, Center, COVID-19, Infection, Risk, FDA, HIV-2, Food, Sale, OraSure Technologies, Emory University, HIV, Privacy, Antibody, Company, Intellectual property, HIV/AIDS denialism, HIV-1, Diagnosis of HIV/AIDS, Forward-looking statement, Program, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, OTC, Technology, Public health, CDC, Solution, Uncertainty, Annual report, Coronavirus, OraQuick, NASDAQ, Korea Disease Control and Prevention Agency, Collection, WHO, Research, Pharmacy, GLOBE, COVID-19 testing, SEC, Awareness, Centers for Disease Control and Prevention timeline, Hospital, Patent, Disagreement, Informatics, Vaccine, Pharmaceutical industry, Diagnosis

This program follows a successful collaborative pilot program by the same name, for which OraSure also supplied tests.

Key Points: 
  • This program follows a successful collaborative pilot program by the same name, for which OraSure also supplied tests.
  • As part of the program, OraSure will provide up to one million OraQuick In-Home HIV tests over a five- year period.
  • The program will target populations that are disproportionately affected by HIV and less likely to have access to key prevention services.
  • The OraQuick In-Home HIV Test is the first and only oral fluid rapid over-the-counter (OTC) HIV test approved in the U.S.

The Rockefeller Foundation Pledges US$15 Million to Global Fund to Fight AIDS, Tuberculosis, and Malaria

Retrieved on: 
Monday, September 19, 2022
Fund, TB, Workforce, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Twitter, Rockefeller Foundation, COVID-19, Developing country, Mark R. Dybul, Tuberculosis, HIV, NEW, Senior, Face, Partnership, Diagnosis of HIV/AIDS, History, Technology, Public health, University-National Oceanographic Laboratory System, Foundation, Science, US, Death, Research, Conference, AIDS, Infection, Yellow fever vaccine, Pharmaceutical industry, Vaccine, Malaria, Health

NEW YORK, Sept. 19, 2022 /PRNewswire/ -- The Rockefeller Foundation announces it will commit US$15 million to the Global Fund to Fight AIDS, tuberculosis, and malaria ahead of the Fund's Seventh Replenishment Conference on Wednesday, September 21. This year, the Global Fund partnership aims to raise US$18 billion to protect hard-fought gains against these infectious diseases in the face of Covid-19 and to finance ongoing projects through 2025.

Key Points: 
  • "Fifty million people are alive today because of the Global Fund's work to fight HIV, tuberculosis, and malaria," saidDr.
  • "As Covid-19 and other crises continue to undermine progress against these and other public health threats, The Rockefeller Foundation is proud to recommit to the Global Fund so it can restart progress and finish the job."
  • This year, The Rockefeller Foundation's Global Fund pledge will finance the Laboratory Systems Strengthening Catalytic Fund, a mechanism for accelerating the development of public health laboratories across low- and middle-income countries (LMICs).
  • "The Global Fund gives labs the resources to expand their workforce and build networks for sharing information about emerging threats.